

Hong Kong Science and Technology Parks Corporation sends out the below press release on behalf of its partner company – Cellomics.

**Press Release**

For Immediate Release

**HKSTP Partner Company Cellomics Secured Strategic Investment from  
China Taiping's Innovation and Technology Venture Fund**

- Rooted in Hong Kong Science Park, Cellomics received a strategic equity investment from Taiping HK I&T Fund under China Taiping and established a strategic partnership with Taiping General Insurance.
- This strategic equity investment will accelerate Cellomics' innovative product pipelines and expand its commercial capabilities.
- The collaboration once again demonstrates Hong Kong's position as a fast-growing biomedical technology hub and promotes the development of innovation and technology in the Greater Bay Area.

**(Hong Kong, 12 July 2023)** – Hong Kong Science and Technology Parks Corporation (HKSTP) congratulates its partner company, Cellomics Holdings Limited, for receiving a strategic equity investment from Taiping Hong Kong Insurance Innovation and Technology Venture Fund (Taiping HK I&T Fund) under China Taiping Insurance Group Co., Ltd. (China Taiping), and establishing a strategic partnership with Taiping General Insurance Co., Ltd. Shenzhen Branch (Taiping General Insurance), a subsidiary of China Taiping. This collaboration clearly demonstrates Hong Kong's position as a fast-growing biomedical technology hub.

Cellomics announced recently that it has secured a strategic equity investment from Taiping HK I&T Fund. The funding provides momentum for Cellomics to accelerate the company's innovative product pipelines and expand the commercial capabilities. The investment in Cellomics is an example of China Taiping's mission to promote the development of innovation and technology in the Guangdong-Hong Kong-Macao Greater Bay Area, and to better serve the "Health China 2030" strategy to improve the people's livelihood.

Meanwhile, Cellomics established a strategic partnership with Taiping General Insurance to jointly develop health service products. Through the new model of "service + insurance", the two companies co-launched the "Taiping-Cellomics" health service plan, integrating innovative technology, insurance protection, medical services and health management, to provide more comprehensive, efficient, and advanced health care services for better serving the community, and to contribute to the development of the Guangdong-Hong Kong-Macao Greater Bay Area.

Cellomics Holdings Limited is a biotech company rooted in Hong Kong Science Park and developing rapidly in recent years. It is focused on the development and commercialization of liquid biopsy products for cancer screening, precision diagnosis, and disease monitoring. Its subsidiary Cellomics

Page 2 of 3

International Limited is supported by HKSTP's Incu-Bio programme. Incu-Bio provides biotech startups with lab facilities, business support, investment opportunities and financial aid, turning their innovative ideas into market products. Cellomics' core technology and R&D team come from top international biomedical institutions such as City University of Hong Kong, Tsinghua University, University of Edinburgh, University of Copenhagen, and Baylor College of Medicine. Cellomics develops products and services for early cancer screening, precision diagnosis, and disease monitoring. Its first-generation circulating tumor cell (CTC) sorting instrument and digital PCR instrument have received market approval from NMPA. It also offers the self-developed CTC single-cell sequencing service via its accredited medical laboratory in Shenzhen.

Taiping HK I&T Fund was established by Taiping Financial Holdings Co., Ltd., an overseas investment platform of China Taiping, focusing on medical, health, elderly care, and related technology fields. Based in Hong Kong, the Fund is actively investing in high-quality equity projects with long-term investment value and serving the "Health China 2023" national strategy, exploring investment opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area. China Taiping is in the Fortune Global 500 list for five consecutive years.



**Photo 1:** Cellomics and Taiping General Insurance established a strategic partnership to jointly launch the "Taiping-Cellomics" health service plan. Among those attending the launching ceremony included Ms. Peng Yunping, Deputy General Manager of Taiping General Insurance (fourth from right), Professor Michael Yang, Co-founder of Cellomics and Senior Vice President of City University of Hong Kong (fifth from right), Mr. Xu Shaowu, General Manager of Taiping General Insurance (Shenzhen) (fifth from left), Ms. Jenny Zhang, CEO of Cellomics (Shenzhen) (third from right), Dr. Henry Zou, Co-founder and Vice President of Cellomics (first from right).

###



Page 3 of 3

### **About Hong Kong Science and Technology Parks Corporation**

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that supported over 10 unicorns and Hong Kong's leading R&D hub with nearly 13,000 research professionals and over 1,300 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimaged for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at [www.hkstp.org](http://www.hkstp.org).

### **About Cellomics**

Cellomics is a biotech company with leading innovative technologies focused on the research and development, production, and commercialization of liquid biopsy products and services for cancer screening, precision diagnosis, and disease monitoring. Cellomics' core technology and R&D team come from top international biomedical institutions such as City University of Hong Kong, Tsinghua University, University of Edinburgh, University of Copenhagen, Baylor College of Medicine, and City of Hope Medical Center. Cellomics develops and produces circulating tumor cell (CTC) sorting instrument and reagents, digital PCR instrument and reagents, and also offers early cancer screening and liquid biopsy services via its accredited medical laboratories in Mainland China and Hong Kong.

#### **Media Contact:**

**Hong Kong Science and Technology Parks Corporation**  
Raven Hui  
Tel: +852 2629 2327  
Email: [raven.hui@hkstp.org](mailto:raven.hui@hkstp.org)

**Edelman Public Relations**  
Sonia Leung  
Tel: +852 2837 4775 / 9684 9460  
Email: [Sonia.Leung@edelman.com/](mailto:Sonia.Leung@edelman.com/)  
[Edelmanhkstppr@edelman.com](mailto:Edelmanhkstppr@edelman.com)